Atara Biotherapeutics Inc (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 7,800 shares of the firm’s stock in a transaction that occurred on Thursday, December 13th. The shares were sold at an average price of $42.66, for a total transaction of $332,748.00. Following the transaction, the chief executive officer now directly owns 733,285 shares of the company’s stock, valued at approximately $31,281,938.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Shares of ATRA opened at $41.72 on Friday. Atara Biotherapeutics Inc has a twelve month low of $14.50 and a twelve month high of $54.45.
Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($1.29) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.13) by ($0.16). On average, analysts forecast that Atara Biotherapeutics Inc will post -4.82 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently made changes to their positions in the stock. State of Wisconsin Investment Board increased its position in shares of Atara Biotherapeutics by 53.9% during the second quarter. State of Wisconsin Investment Board now owns 41,400 shares of the biotechnology company’s stock valued at $1,521,000 after acquiring an additional 14,500 shares in the last quarter. Rhumbline Advisers increased its position in shares of Atara Biotherapeutics by 16.9% during the second quarter. Rhumbline Advisers now owns 39,238 shares of the biotechnology company’s stock valued at $1,442,000 after acquiring an additional 5,673 shares in the last quarter. United Services Automobile Association increased its position in shares of Atara Biotherapeutics by 28.4% during the second quarter. United Services Automobile Association now owns 8,132 shares of the biotechnology company’s stock valued at $299,000 after acquiring an additional 1,797 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Atara Biotherapeutics by 35.6% during the third quarter. JPMorgan Chase & Co. now owns 1,202,912 shares of the biotechnology company’s stock valued at $49,741,000 after acquiring an additional 315,921 shares in the last quarter. Finally, Principal Financial Group Inc. bought a new stake in shares of Atara Biotherapeutics during the first quarter valued at approximately $214,000.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Featured Story: Growth Stocks, What They Are, What They Are Not
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.